Pengfei Xu

Title: Innovations of Pengfei Xu in Nuclear Medicine

Introduction

Pengfei Xu is a notable inventor based in Shandong, China. He has made significant contributions to the fields of nuclear medicine and molecular imaging. With a total of 3 patents, his work focuses on developing advanced compounds for medical applications.

Latest Patents

One of his latest patents is titled "Dual-targeting compound and preparation method and application thereof." This invention relates to a dual-targeting compound that exhibits high affinity for both fibroblast activation protein (FAP) and integrin αβ targets in tumors. The compound is designed to enhance the uptake and retention time in tumors, making it a promising candidate for diagnostic and therapeutic applications.

Another significant patent is the "Truncated Evans Blue modified fibroblast activation protein inhibitor, preparation method and application thereof." This compound combines truncated Evans Blue with a fibroblast activation protein inhibitor and a nuclide chelating group. It is engineered to improve blood circulation half-life and enhance tumor uptake, making it suitable for nuclide therapy and imaging.

Career Highlights

Pengfei Xu is associated with Yantai Lannacheng Biotechnology Co., Ltd., where he continues to innovate in the field of biotechnology. His work is characterized by a strong focus on developing compounds that can significantly impact cancer treatment and diagnostics.

Collaborations

He collaborates with notable colleagues, including Xiaoyuan Chen and Zhide Guo, to further advance research and development in his field.

Conclusion

Pengfei Xu's contributions to nuclear medicine through his innovative patents demonstrate his commitment to improving medical technologies. His work has the potential to significantly enhance the diagnosis and treatment of diseases characterized by overexpression of specific targets.